I

ISD-Immunotech

7 employees

ISD-Immunotech develops a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Medical
Information Technology

Date founded

2013

Funding rounds raised

I

ISD-Immunotech raised undisclosed on July 1, 2020

Investors: Novo Holdings

FAQ